Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ROS1

Gene summary for ROS1

Gene summary.

Gene information	Species	Human
	Gene symbol	ROS1
	Gene ID	6098
	Gene name	ROS proto-oncogene 1, receptor tyrosine kinase
	Gene Alias	MCF3
	Cytomap	6q22.1
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	P08922

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
6098	ROS1	P36T-E	Human	Esophagus	ESCC	7.91e-07	2.65e-01	0.1187
6098	ROS1	P49T-E	Human	Esophagus	ESCC	7.48e-03	5.45e-01	0.1768
6098	ROS1	P62T-E	Human	Esophagus	ESCC	2.57e-02	1.28e-01	0.1302
6098	ROS1	P107T-E	Human	Esophagus	ESCC	3.76e-35	9.87e-01	0.171
6098	ROS1	TD9	Human	Lung	IAC	2.29e-02	4.31e-01	0.088
6098	ROS1	RNA-P10T2-P10T2-1	Human	Lung	AAH	7.35e-09	1.29e+00	-0.1271
6098	ROS1	RNA-P10T2-P10T2-2	Human	Lung	AAH	6.28e-12	1.42e+00	-0.1406
6098	ROS1	RNA-P10T2-P10T2-3	Human	Lung	AAH	3.37e-12	1.43e+00	-0.1408
6098	ROS1	RNA-P10T2-P10T2-4	Human	Lung	AAH	1.91e-14	1.54e+00	-0.138
6098	ROS1	RNA-P17T-P17T-2	Human	Lung	IAC	9.92e-05	6.11e-01	0.3371
6098	ROS1	RNA-P17T-P17T-4	Human	Lung	IAC	1.21e-05	5.96e-01	0.343
6098	ROS1	RNA-P17T-P17T-6	Human	Lung	IAC	6.46e-04	5.65e-01	0.3385
6098	ROS1	RNA-P17T-P17T-8	Human	Lung	IAC	3.82e-05	4.47e-01	0.3329
6098	ROS1	RNA-P18T-P18T-8	Human	Lung	IAC	4.28e-03	1.25e+00	0.1151
6098	ROS1	RNA-P23T2-P23T2-1	Human	Lung	MIAC	5.56e-05	1.32e+00	-0.037
6098	ROS1	RNA-P23T2-P23T2-2	Human	Lung	MIAC	7.61e-03	1.07e+00	-0.028
6098	ROS1	RNA-P23T2-P23T2-4	Human	Lung	MIAC	1.00e-05	1.38e+00	-0.0272
6098	ROS1	RNA-P24T2-P24T2-2	Human	Lung	IAC	4.40e-04	1.38e+00	0.0057
6098	ROS1	RNA-P25T1-P25T1-1	Human	Lung	AIS	5.81e-31	1.35e+00	-0.2116
6098	ROS1	RNA-P25T1-P25T1-2	Human	Lung	AIS	7.54e-17	1.42e+00	-0.1941

Page: 1 2

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0016049110	Esophagus	ESCC	cell growth	289/8552	482/18723	1.29e-10	3.77e-09	289
GO:000155819	Esophagus	ESCC	regulation of cell growth	248/8552	414/18723	2.97e-09	6.45e-08	248
GO:000206420	Esophagus	ESCC	epithelial cell development	136/8552	220/18723	9.50e-07	1.21e-05	136
GO:003367420	Esophagus	ESCC	positive regulation of kinase activity	260/8552	467/18723	7.26e-06	7.22e-05	260
GO:00319294	Esophagus	ESCC	TOR signaling	79/8552	126/18723	8.57e-05	6.21e-04	79
GO:00182124	Esophagus	ESCC	peptidyl-tyrosine modification	202/8552	378/18723	1.34e-03	6.39e-03	202
GO:00320061	Esophagus	ESCC	regulation of TOR signaling	63/8552	104/18723	1.55e-03	7.29e-03	63
GO:00181084	Esophagus	ESCC	peptidyl-tyrosine phosphorylation	200/8552	375/18723	1.60e-03	7.45e-03	200
GO:0002066	Esophagus	ESCC	columnar/cuboidal epithelial cell development	29/8552	44/18723	5.41e-03	2.02e-02	29
GO:00610417	Liver	NAFLD	regulation of wound healing	39/1882	134/18723	5.52e-10	1.28e-07	39
GO:00420607	Liver	NAFLD	wound healing	84/1882	422/18723	6.56e-10	1.37e-07	84
GO:0042730	Liver	NAFLD	fibrinolysis	15/1882	25/18723	1.26e-09	2.30e-07	15
GO:0030195	Liver	NAFLD	negative regulation of blood coagulation	21/1882	49/18723	2.42e-09	4.05e-07	21
GO:1900047	Liver	NAFLD	negative regulation of hemostasis	21/1882	50/18723	3.78e-09	5.40e-07	21
GO:0030193	Liver	NAFLD	regulation of blood coagulation	24/1882	66/18723	9.30e-09	1.26e-06	24
GO:0050819	Liver	NAFLD	negative regulation of coagulation	21/1882	53/18723	1.33e-08	1.69e-06	21
GO:1900046	Liver	NAFLD	regulation of hemostasis	24/1882	68/18723	1.84e-08	2.09e-06	24
GO:0061045	Liver	NAFLD	negative regulation of wound healing	26/1882	78/18723	1.86e-08	2.09e-06	26
GO:19030347	Liver	NAFLD	regulation of response to wounding	41/1882	167/18723	4.70e-08	4.58e-06	41
GO:0050818	Liver	NAFLD	regulation of coagulation	24/1882	71/18723	4.80e-08	4.60e-06	24

Page: 1 2 3 4 5 6

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ROS1

SNV

Missense_Mutation

c.580N>T

p.Pro194Ser

p.P194S

P08922

protein_coding

deleterious(0)

benign(0.433)

TCGA-A2-A0CR-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

ROS1

SNV

Missense_Mutation

novel

c.4714A>C

p.Thr1572Pro

p.T1572P

P08922

protein_coding

deleterious(0)

benign(0.211)

TCGA-A2-A1FW-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cytoxan

ROS1

SNV

Missense_Mutation

c.1786N>A

p.Glu596Lys

p.E596K

P08922

protein_coding

tolerated_low_confidence(0.71)

benign(0.014)

TCGA-A8-A095-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

ROS1

SNV

Missense_Mutation

c.3546N>T

p.Arg1182Ser

p.R1182S

P08922

protein_coding

tolerated(0.74)

benign(0.027)

TCGA-A8-A09A-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

ROS1

SNV

Missense_Mutation

c.565C>T

p.His189Tyr

p.H189Y

P08922

protein_coding

tolerated(0.36)

possibly_damaging(0.747)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ROS1

SNV

Missense_Mutation

c.6797C>G

p.Thr2266Arg

p.T2266R

P08922

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.83)

TCGA-AR-A0TP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

ROS1

SNV

Missense_Mutation

rs62430836

c.3932G>A

p.Arg1311Gln

p.R1311Q

P08922

protein_coding

tolerated(0.14)

benign(0)

TCGA-BH-A0E2-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

ROS1

SNV

Missense_Mutation

novel

c.6443G>A

p.Gly2148Glu

p.G2148E

P08922

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-BH-A0H5-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

ROS1

SNV

Missense_Mutation

c.6702C>A

p.Asn2234Lys

p.N2234K

P08922

protein_coding

tolerated(0.92)

benign(0.015)

TCGA-BH-A18J-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

ROS1

SNV

Missense_Mutation

rs865940125

c.1652N>T

p.Ser551Phe

p.S551F

P08922

protein_coding

tolerated(0.11)

benign(0.006)

TCGA-BH-A18K-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR		Imidazo[1,2-b]pyridazine derivative 2
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR		ENTRECTINIB	ENTRECTINIB	28183697
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR	inhibitor	HESPERADIN	HESPERADIN	19035792
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR		CRIZOTINIB	CRIZOTINIB	23724914,25733882,25351743,25688157,26372962
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR		AZD3463		26372962
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR		TPX-0005
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR	inhibitor	CRIZOTINIB	CRIZOTINIB
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR		DS6051b
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR		CYC-116	CYC-116
6098	ROS1	TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR		CRIZOTINIB	CRIZOTINIB	29596029,23724914,25264305,24875859,25922291,22215748,25688157,26372962,25667280,30980071,29333528

Page: 1 2 3 4 5 6 7